

# Polycystic Kidney Disease Market - A Global and Regional Analysis: Focus on Disease Type, Treatment, Country, and Region - Analysis and Forecast, 2026-2036

<https://marketpublishers.com/r/PC8C9C6B24EAEN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: PC8C9C6B24EAEN

## Abstracts

The global polycystic kidney disease (PKD) market is experiencing significant growth, driven by increasing prevalence, advancements in treatment options, and heightened awareness. The rising prevalence of chronic kidney diseases (CKD), including PKD, is a significant contributor to the market's expansion. Factors such as genetic mutations, hypertension, and diabetes exacerbate the condition, leading to a higher incidence of end-stage renal disease (ESRD) and increased demand for treatment options. Moreover, enhanced diagnostic methods, including contrast-enhanced ultrasonography (CEUS), magnetic resonance imaging (MRI), and genetic testing, have improved early detection and monitoring of PKD. These advancements facilitate timely interventions, potentially slowing disease progression and improving patient outcomes.

Furthermore, the approval of tolvaptan, the first FDA-approved drug for ADPKD, marked a significant milestone in PKD treatment. Ongoing research and clinical trials are exploring additional therapies, such as lixivaptan and tesevatinib, which aim to address the underlying causes of PKD and offer potential benefits over existing treatments.

In addition, the rising awareness about PKD's genetic nature has led to more families undergoing genetic screening and early detection. Early treatment can help preserve kidney function longer, reducing the risk of progression to ESRD. The development of targeted therapies also offers promising avenues for treating PKD. Emerging treatments aim to address the underlying mechanisms of cyst formation and kidney damage, potentially slowing disease progression and improving patient outcomes. For instance, novel pharmacological agents targeting specific pathways involved in cystogenesis are

under investigation, with some showing early signs of efficacy in clinical trials.

The shift towards personalized or precision medicine in PKD involves tailoring treatment strategies based on individual genetic profiles, disease progression, and response to therapy. This approach aims to optimize treatment efficacy and minimize adverse effects, ensuring that patients receive the most appropriate care for their specific condition. The PKD landscape is ripe with opportunities across various domains, including therapeutic advancements, personalized care, market expansion, and collaborative efforts. Stakeholders who can leverage these opportunities are well-positioned to make significant contributions to the management and treatment of PKD.

North America, particularly the U.S., holds a dominant position in the global PKD market. This leadership is attributed to advanced healthcare infrastructure, high healthcare expenditure, and a robust regulatory environment that supports the development and approval of new treatments. The U.S. Food and Drug Administration's approval of tolvaptan for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) has significantly impacted the market, providing a disease-modifying therapy that slows kidney function decline. Additionally, the presence of major pharmaceutical companies and ongoing research initiatives further bolster the market's growth in this region.

The Asia-Pacific region is experiencing the highest growth in the PKD market, driven by increasing healthcare investments, rising awareness, and a large patient population. Countries such as China, Japan, and India are making significant strides in improving healthcare infrastructure and diagnostic capabilities. For instance, Japan has been at the forefront of genetic research into ADPKD, leading to region-specific treatment guidelines. However, challenges like healthcare disparities and limited access to advanced therapies in rural areas persist, which may affect the equitable distribution of treatment benefits.

The competitive landscape of the polycystic kidney disease (PKD) market is shaped by an intersection of established pharmaceutical companies, innovative biotech firms, and a growing focus on personalized, precision medicine. The market is experiencing dynamic growth as new treatments and therapies are developed to manage and slow the progression of the disease, particularly in Autosomal Dominant Polycystic Kidney Disease (ADPKD). Key players in this landscape include Otsuka Pharmaceutical, Novartis, Pfizer, and Vertex Pharmaceuticals, each contributing to the development of cutting-edge therapies aimed at treating PKD.

**Market Segmentation:**

## Segmentation 1: by Disease Type

Autosomal Dominant Form

Autosomal Recessive Form

Familial Nephronophthisis

Medullary Cystic Kidney Disease

## Segmentation 2: by Region

North America

Europe

Asia-Pacific

Rest-of-the-World

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at [order@marketpublishers.com](mailto:order@marketpublishers.com) with your request.

This report will be delivered in 7-10 working days.

## Contents

Executive Summary  
Scope and Definition  
Market/Product Definition  
Key Questions Answered  
Analysis and Forecast Note

### **1. GLOBAL POLYCYSTIC KIDNEY DISEASE MARKET: INDUSTRY OUTLOOK**

1.1 Industry Outlook  
    1.1.1 Market Introduction  
    1.1.2 Epidemiological Analysis of Polycystic Kidney Disease Market  
    1.1.3 Introduction on Polycystic Kidney Disease Market  
1.2 Pipeline Analysis  
1.3 Treatment Landscape  
1.4 Regulatory Landscape of Polycystic Kidney Disease Market  
    1.4.1 Legal Requirement and Framework in the U.S.  
    1.4.2 Legal Requirement and Framework in the E.U.  
    1.4.3 Legal Requirement and Framework in Japan  
    1.4.4 Legal Requirement and Framework in Rest-of-the-World  
1.5 Market Dynamics  
    1.5.1 Impact Analysis  
    1.5.2 Market Drivers  
    1.5.3 Market Restraint  
    1.5.4 Market Opportunities

### **2. GLOBAL POLYCYSTIC KIDNEY DISEASE MARKET (BY DISEASE TYPE), \$MILLION, 2025-2036**

2.1 Overview  
2.2 Autosomal Dominant Form  
2.3 Autosomal Recessive Form  
2.4 Familial Nephronophthisis  
2.5 Medullary Cystic Kidney Disease

### **3. GLOBAL POLYCYSTIC KIDNEY DISEASE MARKET (BY TREATMENT), \$MILLION, 2025-2036**

- 3.1 Overview
- 3.2 Pharmacological
  - 3.2.1 RAS Inhibitors
  - 3.2.2 Tyrosine Kinase Inhibitors
  - 3.2.3 Other Drugs
- 3.3 Non-Pharmacological
  - 3.3.1 Surgical Treatment
  - 3.3.2 Supportive Therapies

## **4. GLOBAL POLYCYSTIC KIDNEY DISEASE MARKET, BY REGION, \$MILLION, 2025-2036**

- 4.1 Overview
- 4.2 North America
  - 4.2.1 Business Drivers
  - 4.2.2 Business Challenges
  - 4.2.3 Market Sizing and Forecast
    - 4.2.3.1 North America Polycystic Kidney Disease Market, by Country
      - 4.2.3.1.1 U.S.
      - 4.2.3.1.2 Canada
- 4.3 Europe
  - 4.3.1 Business Drivers
  - 4.3.2 Business Challenges
  - 4.3.3 Market Sizing and Forecast
    - 4.3.3.1 Europe Polycystic Kidney Disease Market, by Country
      - 4.3.3.1.1 Germany
      - 4.3.3.1.2 U.K.
      - 4.3.3.1.3 France
      - 4.3.3.1.4 Italy
      - 4.3.3.1.5 Spain
      - 4.3.3.1.6 Rest-of-Europe
- 4.4 Asia-Pacific
  - 4.4.1 Business Drivers
  - 4.4.2 Business Challenges
  - 4.4.3 Market Sizing and Forecast
    - 4.4.3.1 Asia-Pacific Polycystic Kidney Disease Market, by Country
      - 4.4.3.1.1 Japan
      - 4.4.3.1.2 China
      - 4.4.3.1.3 India

- 4.4.3.1.4 Australia
- 4.4.3.1.5 South Korea
- 4.4.3.1.6 Rest-of-APAC

#### 4.5 Rest-of-the-world

- 4.5.1 Business Drivers
- 4.5.2 Business Challenges
- 4.5.3 Market Sizing and Forecast

## **5. COMPETITIVE LANDSCAPE AND COMPANY PROFILES**

### 5.1 Competitive Landscape

- 5.1.1 Overview
- 5.1.2 Key Developments and Strategies
  - 5.1.2.1 Funding Activities
  - 5.1.2.2 Mergers and Acquisitions
  - 5.1.2.3 Regulatory Approvals
  - 5.1.2.4 Partnerships, Collaborations and Business Expansions
- 5.1.3 Growth-Share Analysis (by Company)

### 5.2 Company Profiles

- 5.2.1 Ostuka Pharmaceuticals Co. Ltd.
  - 5.2.1.1 Overview
  - 5.2.1.2 Product Portfolio
  - 5.2.1.3 Target Customers
  - 5.2.1.4 Key Personnel
  - 5.2.1.5 Analyst View

#### 5.2.2 AbbVie, Inc.

- 5.2.2.1 Overview
- 5.2.2.2 Product Portfolio
- 5.2.2.3 Target Customers
- 5.2.2.4 Key Personnel
- 5.2.2.5 Analyst View

#### 5.2.3 Eli Lilly and Company

- 5.2.3.1 Overview
- 5.2.3.2 Product Portfolio
- 5.2.3.3 Target Customers
- 5.2.3.4 Key Personnel
- 5.2.3.5 Analyst View

#### 5.2.4 Bayer AG

- 5.2.4.1 Overview

- 5.2.4.2 Product Portfolio
- 5.2.4.3 Target Customers
- 5.2.4.4 Key Personnel
- 5.2.4.5 Analyst View
- 5.2.5 Novartis AG
  - 5.2.5.1 Overview
  - 5.2.5.2 Product Portfolio
  - 5.2.5.3 Target Customers
  - 5.2.5.4 Key Personnel
  - 5.2.5.5 Analyst View
- 5.2.6 Vertex Pharmaceuticals
  - 5.2.6.1 Overview
  - 5.2.6.2 Product Portfolio
  - 5.2.6.3 Target Customers
  - 5.2.6.4 Key Personnel
  - 5.2.6.5 Analyst View
- 5.2.7 Galapagos NV
  - 5.2.7.1 Overview
  - 5.2.7.2 Product Portfolio
  - 5.2.7.3 Target Customers
  - 5.2.7.4 Key Personnel
  - 5.2.7.5 Analyst View
- 5.2.8 Johnson and Johnson
  - 5.2.8.1 Overview
  - 5.2.8.2 Product Portfolio
  - 5.2.8.3 Target Customers
  - 5.2.8.4 Key Personnel
  - 5.2.8.5 Analyst View
- 5.2.9 Reata Pharmaceuticals
  - 5.2.9.1 Overview
  - 5.2.9.2 Product Portfolio
  - 5.2.9.3 Target Customers
  - 5.2.9.4 Key Personnel
  - 5.2.9.5 Analyst View
- 5.2.10 Renasant Bio
  - 5.2.10.1 Overview
  - 5.2.10.2 Product Portfolio
  - 5.2.10.3 Target Customers
  - 5.2.10.4 Key Personnel

5.2.10.5 Analyst View

## **6. RESEARCH METHODOLOGY**

## List Of Figures

### LIST OF FIGURES

Figure: Polycystic Kidney Disease Market (by Scenario), \$Million, 2025, 2030, and 2036

Figure: Global Polycystic Kidney Disease Market, 2025 and 2036

Figure: Global Polycystic Kidney Disease Market Key Trends, Impact Analysis

Figure: North America Polycystic Kidney Disease Market, \$Million, 2025-2036

Figure: Europe Polycystic Kidney Disease Market, \$Million, 2025-2036

Figure: Asia-Pacific Polycystic Kidney Disease Market, \$Million, 2025-2036

Figure: Rest-of-the-World Polycystic Kidney Disease Market, \$Million, 2025-2036

## List Of Tables

### LIST OF TABLES

Table: Market Snapshot

Table: Market Dynamics

Table: Global Polycystic Kidney Disease Market (by Disease Type), \$Million, 2025-2036

Table: Global Polycystic Kidney Disease Market (by Treatment), \$Million, 2025-2036

Table: Global Polycystic Kidney Disease Market (by Region), \$Million, 2025-2036

## I would like to order

Product name: Polycystic Kidney Disease Market - A Global and Regional Analysis: Focus on Disease Type, Treatment, Country, and Region - Analysis and Forecast, 2026-2036

Product link: <https://marketpublishers.com/r/PC8C9C6B24EAEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PC8C9C6B24EAEN.html>